S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:PBYI

Puma Biotechnology (PBYI) Stock Price, News & Analysis

$5.58
-0.02 (-0.36%)
(As of 03/27/2024 ET)
Today's Range
$5.38
$5.74
50-Day Range
$4.30
$7.40
52-Week Range
$2.13
$7.73
Volume
357,775 shs
Average Volume
789,730 shs
Market Capitalization
$269.01 million
P/E Ratio
12.13
Dividend Yield
N/A
Price Target
$7.00

Puma Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
25.4% Upside
$7.00 Price Target
Short Interest
Healthy
8.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Puma Biotechnology in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$291,001 Sold Last Quarter
Proj. Earnings Growth
3.45%
From $0.29 to $0.30 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.89 out of 5 stars

Medical Sector

236th out of 939 stocks

Pharmaceutical Preparations Industry

103rd out of 436 stocks

PBYI stock logo

About Puma Biotechnology Stock (NASDAQ:PBYI)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

PBYI Stock Price History

PBYI Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
Puma Biotechnology Inc.
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
Puma Biotechnology Inc PBYI
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PBYI
Employees
185
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+25.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$21.59 million
Pretax Margin
9.62%

Debt

Sales & Book Value

Annual Sales
$235.60 million
Cash Flow
$0.69 per share
Book Value
$1.12 per share

Miscellaneous

Free Float
37,264,000
Market Cap
$269.01 million
Optionable
Optionable
Beta
1.32
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

PBYI Stock Analysis - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings
or view top-rated stocks.

What is Puma Biotechnology's stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for Puma Biotechnology's stock. Their PBYI share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 25.4% from the stock's current price.
View analysts price targets for PBYI
or view top-rated stocks among Wall Street analysts.

How have PBYI shares performed in 2024?

Puma Biotechnology's stock was trading at $4.33 at the start of the year. Since then, PBYI stock has increased by 28.9% and is now trading at $5.58.
View the best growth stocks for 2024 here
.

Are investors shorting Puma Biotechnology?

Puma Biotechnology saw a decline in short interest in March. As of March 15th, there was short interest totaling 3,330,000 shares, a decline of 18.6% from the February 29th total of 4,090,000 shares. Based on an average daily trading volume, of 603,600 shares, the short-interest ratio is currently 5.5 days. Currently, 9.0% of the shares of the stock are sold short.
View Puma Biotechnology's Short Interest
.

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBYI earnings forecast
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) released its earnings results on Thursday, February, 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.33 by $0.07. The biopharmaceutical company had revenue of $72.20 million for the quarter, compared to analysts' expectations of $73.22 million. Puma Biotechnology had a trailing twelve-month return on equity of 58.21% and a net margin of 9.16%.

What guidance has Puma Biotechnology issued on next quarter's earnings?

Puma Biotechnology issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $214.0 million-$225.0 million, compared to the consensus revenue estimate of $244.7 million.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.99%), Vanguard Group Inc. (7.89%), Great Point Partners LLC (2.30%), Dimensional Fund Advisors LP (1.05%), Sei Investments Co. (0.61%) and GSA Capital Partners LLP (0.55%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Langley Steinert, Maximo F Nougues, Michael Patrick Miller and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PBYI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners